Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy and congenital blindness, and clinical trials are in progress 58 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [58]
In the citing paper
“preclinical and clinical studies have demonstrated dose-dependent inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2–8)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [4]
In the citing paper
“Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal 61”
From Autism spectrum disorder (2020) · cites this paper as [61]
In the citing paper
“Especially considering the ability of the recombinant AAV genome to persist as an episome in post-mitotic cells, such as neurons, which ensures long-term expression even after a single administration [130-132].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [132]
In the citing paper
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedDeaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citationBayley Scales of Infant and Toddler Development, Third Edition
Bayley, N. (2012) · PsycTESTS Dataset · doi:10.1037/t14978-000 · Cited by 1,175
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961 · cited 4×
“Viral upper respiratory tract infection 0 0 3 3 (25) 3 3 (20)”
InfluentialAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
de Onis, M., Onyango, A. W., Van den Broeck, J., Chumlea, W. C., & Martorell, R. (2004) · Food and Nutrition Bulletin · doi:10.1177/15648265040251s105 · Cited by 529
Research works printed but not linked: 1
- Hoyert DL, 2012, Natl Vital Stat Rep, 61, 1
Cited by
Items 601–700 of 1,005
Quantitative MR neurography biomarkers in 5q-linked spinal muscular atrophy
Kollmer, J., Hilgenfeld, T., Ziegler, A., Saffari, A., Sam, G., Hayes, J. M., Pietsch, A., Jost, M., Heiland, S., Bendszus, M., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007945 · Cited by 36
“Ambulatory patients with SMA type IIIb were evaluated with the 6-minute walk test.(7,23)”
MethodKizina, K., Stolte, B., Totzeck, A., Bolz, S., Fleischer, M., Mönninghoff, C., Guberina, N., Oldenburg, D., Forsting, M., Kleinschnitz, C., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01166 · Cited by 38
“Furthermore, there is a major focus on gene therapy, such as onasemnogen abeparvovec, a viral vector with DNA encoding for the survival of motor neuron (SMN) protein, which has been approved by the FDA for treatment of SMA type 1 (50).”
BackgroundThe Unusual Properties of the AAV Inverted Terminal Repeat
Berns, K. I. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.017 · Cited by 35
“38 A major reason that AAV has found favor as a vector for human gene therapy is that until recently there has been no known association with human disease.”
Khatib, T. Z., Osborne, A., Yang, S., Ali, Z., Jia, W., Manyakin, I., Hall, K., Watt, R., Widdowson, P. S., & Martin, K. R. G. (2021) · Science Advances · doi:10.1126/sciadv.abd2590 · Cited by 38
Repurposing eflornithine to treat a patient with a rare ODC1 gain-of-function variant disease
Rajasekaran, S., Bupp, C. P., Leimanis, M. L., Shukla, A., Russell, C., Junewick, J. J., Gleason, E. G., VanSickle, E., Edgerly, Y. M., Wittmann, B. M., et al. (2021) · eLife · doi:10.7554/elife.67097 · Cited by 34
Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen
Rich, K. A., Fox, A., Yalvac, M., Heintzman, S., Tellez, M., Bartlett, A., Severyn, S., Linsenmayer, M., Kelly, K., Reynolds, J., et al. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210735 · Cited by 39
“Gene therapy approaches for SMA target SMN by either replacing absent SMN1 (via gene replacement therapy onasemnogene abeparvovec [6]) or enhancing SMN2 splicing (via antisense oligonucleotide nusinersen [7] or small molecule splicing enhancer ridsiplam [8, 9]).”
Self-citationKarri, D., Zhang, Y., Chemello, F., Min, Y.-L., Huang, J. H., Kim, J., Mammen, P. P. A., Xu, L., Liu, N., Bassel‐Duby, R., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.004 · Cited by 33
“The clinical efficacy and safety of AAV9 were demonstrated in successful SMA gene-therapy trials.(42) However, AAV can only be effectively delivered once due to the development of a humoral immune response.”
Reece, A. S., Wang, W., & Hulse, G. K. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.04.011 · Cited by 35
Large-scale neurophysiology and single-cell profiling in human neuroscience
Lee, A. T., Chang, E. F., Paredes, M. F., & Nowakowski, T. J. (2024) · Nature · doi:10.1038/s41586-024-07405-0 · Cited by 40
“102).”
Spinal Muscular Atrophy Update in Best Practices: Recommendations for Treatment Considerations
Schroth, M. K., Deans, J., Goebel, D. X. B., Burnette, W. B., Darras, B. T., Elsheikh, B., Felker, M. V., Klein, A., Krueger, J. M., Proud, C. M., et al. (2024) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200374 · Cited by 45
Schellino, R., Boido, M., Borsello, T., & Vercelli, A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00308 · Cited by 39
“Finally, our treatment could represent an effective potential adjuvant to other therapies, like Nusinersen (ISIS 396443), an antisense oligonucleotide (ASO) already used in phase 3 clinical studies to increase the production of full-length SMN2 protein (Adams, 2017; Maharshi and Hasan, 2017), or AVXS-101, an AAV-based…”
BackgroundMethodAdeno‐associated virus‐based Alzheimer's disease mouse models and potential new therapeutic avenues
Ittner, L. M., Klugmann, M., & Ke, Y. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14637 · Cited by 38
“Of highest relevance for the neuroscience community, an AAV9‐based gene therapy encoding SMN protein for the treatment of the devastating childhood disorder spinal muscular atrophy has shown promising safety data and outstanding benefit in clinical trials (Mendell et al., 2017).”
BackgroundTorres‐Benito, L., Schneider, S. M., Rombo, R., Ling, K., Grysko, V., Upadhyay, A., Kononenko, N. L., Rigo, F., Bennett, C. F., & Wirth, B. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.05.008 · Cited by 44
“While SMN-ASOs, small molecules, or SMN gene therapy show promising results in pre- or early-treated symptomatic SMA individuals, treatment in more advanced stages of the disease show onlymoderate or even no effect.(1,31,33,38,39) For these SMA-affected individuals, amelioration or even stopping the disease progressio…”
BackgroundWeber-Adrian, D., Kofoed, R. H., Chan, J. W. Y., Silburt, J., Noroozian, Z., Kügler, S., Hynynen, K., & Aubert, I. (2019) · Theranostics · doi:10.7150/thno.36718 · Cited by 33
“Recent successes in gene therapy clinical trials include improvements in the vision of patients with leber congenital amaurosis (1), and the first life-saving treatment of neurodegeneration in infants with spinal muscular atrophy (2).”
BackgroundThe ties that bind: functional clusters in limb-girdle muscular dystrophy
Barton, E. R., Pacak, C. A., Stoppel, W. L., & Kang, P. B. (2020) · Skeletal Muscle · doi:10.1186/s13395-020-00240-7 · Cited by 38
“Such efforts have accelerated and moved into human clinical trials for genes such as SGCG [108], inspired in part by an FDA-approved gene therapy for spinal muscular atrophy [109] and ongoing human studies of microdystrophin gene therapy for DMD [110].”
BackgroundOjala, K. S., Reedich, E. J., DiDonato, C. J., & Meriney, S. D. (2021) · Brain Sciences · doi:10.3390/brainsci11020194 · Cited by 39
Korecki, A. J., Vargas, J. L. C., Fornés, O., Agostinone, J., Farkas, R. A., Hickmott, J. W., Lam, S. L., Mathelier, A., Zhou, M., Wasserman, W. W., et al. (2021) · Gene Therapy · doi:10.1038/s41434-021-00227-z · Cited by 36
“The recent stunning success of the intravenously delivered rAAV9-augmentation gene therapy to children for spinal muscular atrophy [25, 26] helped propel this approach forward to clinical trials for several devastating incurable diseases (www.”
BackgroundZhang, L., & Wang, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112075 · Cited by 41
New RNA-Based Breakthroughs in Alzheimer’s Disease Diagnosis and Therapeutics
Riscado, M., Baptista, B., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091397 · Cited by 35
Using gene panels in the diagnosis of neuromuscular disorders: A mini-review
Ng, K. W. P., Chin, H.-L. L., Chin, A. X. Y., & Goh, D. L. M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.997551 · Cited by 41
The 2022 yearbook of Neurorestoratology
Huang, H., Bach, J. R., Sharma, H. S., Saberi, H., Jeon, S. R., Guo, X., Shetty, A. K., Hawamdeh, Z. M., Sharma, A., Wild, K. V., et al. (2023) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2023.100054 · Cited by 38
Liver directed adeno‐associated viral vectors to treat metabolic disease
Chuecos, M. A., & Lagor, W. R. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12637 · Cited by 36
“AAV episomal genomes support transcription (5) and protein expression of the therapeutic transgene (6) T A B L E 1 AA V S e x d i ff e r e n c e s r e p o r t e d i n m o u s e L i v e r .”
BackgroundTizzano, E. F., & Zafeiriou, D. (2018) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2018.08.009 · Cited by 35
Chan, J. K. Y., Gil-Fariña, I., Johana, N. B., Rosales, C., Tan, Y. W., Ceiler, J., McIntosh, J., Ogden, B. E., Waddington, S. N., Schmidt, M., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201801391r · Cited by 37
Neurocalcin Delta Knockout Impairs Adult Neurogenesis Whereas Half Reduction Is Not Pathological
Upadhyay, A., Hosseinibarkooie, S., Schneider, S. M., Kaczmarek, A., Torres‐Benito, L., Mendoza-Ferreira, N., Overhoff, M., Rombo, R., Grysko, V., Kye, M. J., et al. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00019 · Cited by 36
Lee, D., Liu, J., Junn, H. J., Lee, E., Jeong, K.-S., & Seol, D. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0334-z · Cited by 45
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
Regensburger, A. P., Wagner, A. L., Danko, V., Jüngert, J., Federle, A., Klett, D., Schüssler, S. C., Büehler, A., Neurath, M. F., Roos, A., et al. (2021) · Photoacoustics · doi:10.1016/j.pacs.2021.100315 · Cited by 35
Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months
Wel, B. D., Schaepdryver, M. D., Poesen, K., & Claeys, K. G. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51625 · Cited by 33
A neural stem cell paradigm of pediatric hydrocephalus
Duy, P. Q., RAKIC, P. T., Alper, S. L., Robert, S. M., Kundishora, A. J., Butler, W. E., Walsh, C. A., Šestan, N., Geschwind, D. H., Jin, S. C., et al. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac341 · Cited by 39
New and developing therapies in spinal muscular atrophy
Kariyawasam, D. S. T., Carey, K. A., Jones, K., & Farrar, M. A. (2018) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2018.03.003 · Cited by 37
Towards developing an ethical framework for decision making in long-term ventilation in children
Ray, S., Brierley, J., Bush, A., Fraser, J. I., Halley, G., Harrop, E. J., & Casanueva, L. (2018) · Archives of Disease in Childhood · doi:10.1136/archdischild-2018-314997 · Cited by 34
Zhang, L., Rossi, A., Lange, L., Meumann, N., Koitzsch, U., Christie, K. A., Nesbit, M. A., Moore, C. B. T., Hacker, U. T., Morgan, M. A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.027 · Cited by 34
“4 Nevertheless, relatively high vector doses are required to obtain therapeutic effects, 6,7 and distinct clinically relevant cell types such as keratinocytes or dendritic cells are refractory toward transduction.”
Intramuscular Delivery of Gene Therapy for Targeting the Nervous System
Tosolini, A. P., & Sleigh, J. N. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00129 · Cited by 32
Weiß, C., Becker, L., Friese, J., Blaschek, A., Hahn, A., Illsinger, S., Schwartz, O., Bernert, G., von der Hagen, M., Husain, R. A., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101092 · Cited by 33
Meadows, A. S., Pineda, R. J., Goodchild, L., Bobo, T. A., & Fu, H. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.04.004 · Cited by 34
Ke, Q., Zhao, Z.-Y., Mendell, J. R., Baker, M. W., Wiley, V. C., Kwon, J. M., Alfano, L. N., Connolly, A. M., Jay, C., Polari, H., et al. (2019) · World Journal of Pediatrics · doi:10.1007/s12519-019-00242-6 · Cited by 33
Self-citationMarcó, S., Haurigot, V., & Bosch, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.217 · Cited by 39
“…clinic for MPSIIIA (NCT01474343) and MPSIIIB Based on results obtained in proof-of-concept studies in small and large animal models of MPSIII, 49,51,53,54,56,81–84,91,96,97,99,102,117–120,125,126 a schematic representation of thepossiblebiodistributionofthegenetherapyproductinpatientsispresented.”
Genome and base editing for genetic hearing loss
Niggemann, P., György, B., & Chen, Z. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107958 · Cited by 36
“, 2017), Luxturna®), spinal muscular atrophy (onasemnogene abeparvovec (Mendell et al., 2017), Zolgensma®) and B-cell malignancies (axicabtagene ciloleucel (Neelapu et al.”
BackgroundBattling Neurodegenerative Diseases with Adeno-Associated Virus-Based Approaches
Mijanović, O., Branković, A., Borovjagin, A. V., Butnaru, D., Bezrukov, E., Sukhanov, R., Shpichka, A., Timashev, P., & Ulasov, I. (2020) · Viruses · doi:10.3390/v12040460 · Cited by 24
“For instance, in the case of Spinal Muscular Atrophy type 1 (SMA1), a single dose of intravenously delivered AAV9 vector carrying a transgene encoding the missing SMN protein resulted in longer survival of patients [33].”
BackgroundYin, S., Ma, L., Shao, T., Zhang, M., Guan, Y., Wang, L., Hu, Y., Chen, X., Han, H., Shen, N., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1744-6 · Cited by 39
Clinical Experience With Gene Therapy in Older Patients With Spinal Muscular Atrophy
Matesanz, S. E., Battista, V., Flickinger, J., Jones, J. N., & Kichula, E. A. (2021) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2021.01.012 · Cited by 34
Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy.
Naveed, A., & Calderon, H. (2021) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-26.5.437 · Cited by 30
Wilton-Clark, H., & Yokota, T. (2022) · Genes · doi:10.3390/genes13020257 · Cited by 38
“Based on these promising findings, and the success of a similar gene-replacement therapy aiming to treat spinal muscular atrophy, multiple commercial research groups have begun clinical trials exploring the therapeutic potential of AAV-delivered microdystrophin for the treatment of DMD [80].”
BackgroundLongitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy
Ngawa, M., Farra, F. D., Marinescu, A.-D., & Servais, L. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231154335 · Cited by 35
Biomarkers in 5q-associated spinal muscular atrophy—a narrative review
Lapp, H. S., Freigang, M., Hagenacker, T., Weiler, M., Wurster, C. D., & Günther, R. (2023) · Journal of Neurology · doi:10.1007/s00415-023-11787-y · Cited by 32
Suppression and Replacement Gene Therapy for KCNH2 -Mediated Arrhythmias
Bains, S., Zhou, W., Dotzler, S. M., Martinez, K., Kim, C. J., Tester, D. J., Ye, D., & Ackerman, M. J. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.122.003719 · Cited by 33
Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): Challenges and Opportunities
Rodriguez-Torres, R. S., Uher, D. T., Gay, E. L., Coratti, G., Young, S. D., Rohwer, A., Muni‐Lofra, R., Vivo, D. C. D., Hirano, M., Glynn, N. W., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103458 · Cited by 36
“Onasemnogene abeparvovec-xioi (Zolgensma, Novartis Gene Therapies, Inc., Bannockburn, IL, USA) is an AAV9-based gene therapy delivered as a one-time intravenous administration to deliver a copy of SMN1 [11].”
BackgroundMendell, J. R., Pozsgai, E. R., Lewis, S., Griffin, D. A., Lowes, L. P., Alfano, L. N., Lehman, K. J., Church, K. R., Reash, N. F., Iammarino, M. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02730-9 · Cited by 35
Self-citationHarkins, A. L., Ambegaokar, P. P., & Keeler, A. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00435 · Cited by 39
“As mentioned, elevations in liver enzymes have been reported in multiple trials for IV delivery of AAV9-SMN for SMA [27,105 – 108].”
InfluentialArokiaraj, C. M., Leone, M. J., Kleyman, M., Chamessian, A. G., Noh, M., Phan, B. N., Lopes, B. C., Corrigan, K. A., Cherupally, V. K., Yeramosu, D., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114876 · Cited by 35
Gene therapy then and now: A look back at changes in the field over the past 25 years
Wang, D., Stevens, G., & Flotte, T. R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.040 · Cited by 37
Neonatal brain-directed gene therapy rescues a mouse model of neurodegenerative CLN6 Batten disease
Holthaus, S.-M. K., Herranz-Martín, S., Massaro, G., Aristorena, M., Hoke, J., Hughes, M. P., Maswood, R. N., Semenyuk, O., Basche, M., Shah, A. Z., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz210 · Cited by 33
A Review of Gene Therapy Delivery Systems for Intervertebral Disc Degeneration
Chen, S., Luo, M., Kou, H., Shang, G., Ji, Y., & Liu, H. (2019) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201020666191024171618 · Cited by 34
In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery
Breuer, C. B., Hanlon, K. S., Natasan, J.-S., Volak, A., Meliani, A., Mingozzi, F., Kleinstiver, B. P., Moon, J. J., & Maguire, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-61518-w · Cited by 32
Swarup, I., MacAlpine, E. M., Mayer, O. H., Lark, R. K., Smith, J. T., Vitale, M. G., Flynn, J. M. “., Anari, J. B., Pediatric Spine Study Group, & Cahill, P. J. (2020) · European Spine Journal · doi:10.1007/s00586-020-06564-8 · Cited by 33
the NatHis-MTM Study Group, Fouarge, E., Monseur, A., Boulanger, B., Annoussamy, M., Seferian, A., Lucia, S. D., Lilien, C., Thielemans, L. A., Paradis, K., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01663-7 · Cited by 31
“In the examples of historical cohorts cited above, survival and need for ventilation support of patients with Pompe disease treated with alglucosidase alfa [13], and motor function scores and motor milestones in spinal muscular atrophy patients treated with onasemnogene abeparvovec-xioi [14] were compared to the natur…”
MethodPeplow, P., & Martinez, B. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.310673 · Cited by 35
‘Channeling’ therapeutic discovery for epileptic encephalopathy through iPSC technologies
Simkin, D., Ambrosi, C. M., Marshall, K. A., Williams, L. A., Eisenberg, J., Gharib, M., Dempsey, G. T., George, A. L., McManus, O. B., & Kiskinis, E. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.001 · Cited by 33
Recent Progress in Macromolecule‐Anchored Hybrid Gold Nanomaterials for Biomedical Applications
Luo, Z., Xu, Y. J., Ye, E., Li, Z., & Wu, Y. (2018) · Macromolecular Rapid Communications · doi:10.1002/marc.201800029 · Cited by 31
Preventing packaging of translatable P5-associated DNA contaminants in recombinant AAV vector preps
Brimble, M. A., Cheng, P.-H., Winston, S. M., Reeves, I. L., Souquette, A., Spence, Y., Zhou, J., Wang, Y.-D., Morton, C. L., Valentine, M., et al. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.008 · Cited by 30
“Dosedependent liver toxicity has been observed sporadically after systemic rAAV administration.(2,4,7,8) While in nearly all cases these symptoms resolve, albeit with therapeutic efficacy loss if untreated, three X-linked myotubular myopathy patients with pre-existing liver pathology experienced severe liver failure a…”
Systematic Review of Motor Function Scales and Patient-Reported Outcomes in Spinal Muscular Atrophy
Wu, J. W., Pepler, L., Maturi, B., Afonso, A. C. F., Sarmiento, J., & Haldenby, R. (2021) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001869 · Cited by 36
“9 mos.(47) There was a rapid increase in the CHOP-INTEND score in the higher-dose cohort (9.”
BackgroundResultAAV genome modification for efficient AAV production
Asaad, W., Volos, P., Maksimov, D. O., Khavina, E. M., Deviatkin, A. A., Mityaeva, O. N., & Volchkov, P. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15071 · Cited by 33
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 34
“Onasemnogene abeparvovec, distinguished as the inaugural gene therapy sanctioned for SMA, facilitates persistent SMN protein expression via a singular intravenous administration, designed to curtail the advancement of the disease (Mendell et al., 2017; Mendell et al., 2021).”
BackgroundWu, Y., Chen, J., & Jong, Y. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01123-z · Cited by 34
“Other diseases being tackled by this approach are spinal muscular atrophy (SMA) (onasemnogene abeparvovec) [7], Duchenne muscular dystrophy (DMD) (delandistrogene moxeparvovec) [8], and sickle cell disease (lovotibeglogeno cutotemce) [9].”
Ethnicity-Based Carrier Screening
King, J. R., & Klugman, S. D. (2018) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2017.10.010 · Cited by 30
Genetic approaches to the treatment of inherited neuromuscular diseases.
Ravi, B., Antonellis, A., Sumner, C., & Lieberman, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz131 · Cited by 27
“This drug has shown marked improvements of survival and motor function in SMA mice in preclinical studies (31–33) and efficacy in infantile SMA patients (34).”
BackgroundGene Therapy for Pompe Disease: The Time is now
Colella, P., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.109 · Cited by 37
Gene therapy for hemophilia: Progress to date and challenges moving forward
Gollomp, K. L., Doshi, B. S., & Arruda, V. R. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.08.012 · Cited by 33
Perego, M. G. L., Galli, N., Nizzardo, M., Govoni, A., Taiana, M. M., Bresolin, N., Comi, G. P., & Corti, S. P. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03492-0 · Cited by 32
Spinal Muscular Atrophy in the Treatment Era
Waldrop, M. A., & Elsheikh, B. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2020.03.002 · Cited by 35
High, K. A. (2020) · Nature Communications · doi:10.1038/s41467-020-19507-0 · Cited by 33
Feeding difficulties in children and adolescents with spinal muscular atrophy type 2
Wadman, R. I., Amicis, R. S. D., Brusa, C., Battezzati, A., Bertoli, S., Davis, T., Main, M. L., Manzur, A. Y., Mastella, C., Munot, P., et al. (2020) · Neuromuscular Disorders · doi:10.1016/j.nmd.2020.12.007 · Cited by 33
Human gene therapy: A scientometric analysis
Zhou, W., & Wang, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111510 · Cited by 34
Chand, D. H., Mitchell, S. L., Sun, R., LaMarca, N. M., Reyna, S. P., & Sutter, T. (2022) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2022.05.001 · Cited by 34
Ramirez-Martinez, A., Zhang, Y., van den Boogaard, M. H., McAnally, J., Rodríguez-Caycedo, C., Chai, A. C., Chemello, F., Massink, M. P. G., Cuppen, I., Elferink, M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159002 · Cited by 32
“Gene therapy has been used successfully in clinical trials to treat genetic neuromuscular disorders such as spinal muscular atrophy (51, 52).”
Stam, M., Wijngaarde, C. A., Bartels, B., Asselman, F., Otto, L. A. M., Habets, L. E., van Eijk, R. P. A., Middelkoop, B. M., Goedee, H. S., de Groot, J. F., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac324 · Cited by 34
“SMA type, n (%) 2 10 (59) 5 (28) 3a 5 (29) 9 (50) 3b 2 (12) 3 (17) 4 0 1 (6) Male gender, n (%) 8 (47) 5 (28) Age in years, mean (SD; range) 34 (12; 13–53) 38 (14; 13–59) Disease duration in years, mean (SD; range) 33 (12; 11–51) 34 (14; 11–59) Ambulant, n (%) 2 (12) 2 (11) MFM score, median (range) 37.”
McGrattan, K. E., Shell, R. D., Hurst-Davis, R., Young, S. D., O’Brien, E. J., Lavrov, A., Wallach, S., LaMarca, N. M., Reyna, S. P., & Darras, B. T. (2023) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-221531 · Cited by 30
“START [20] STR1VE-US [21] STR1VE-EU [22] Combined (N = 11), (N = 22), (N = 32), (N = 65), n (%) n (%) n (%) n (%)”
BackgroundMethodResultInfluentialSelf-citationZhou, H., Hong, Y., Scoto, M., Thomson, A. K., Pead, E., MacGillivray, T., Hernandez‐Gerez, E., Catapano, F., Meng, J., Zhang, Q., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153430 · Cited by 34
“These data show a close association between an early reduction in CNS vascularity and a concurrent or later loss of neurons.”
BackgroundInfluentialPowers, S., Likhite, S. B., Gadalla, K. K. E., Miranda, C. J., Huffenberger, A. J., Dennys, C. N., Foust, K. D., Morales, P. R., Pierson, C. R., Rinaldi, F., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.013 · Cited by 39
Self-citationLeow, D. M.-K., Ng, Y. K., Wang, L. C., Koh, H. W. L., Zhao, T., Khong, Z. J., Tabaglio, T., Narayanan, G., Giadone, R. M., Sobota, R. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173702 · Cited by 32
“Onasemnogene abeparvovec-xio is usually associated with mild to moderate hepatotoxicity within days to a few weeks of treatment (13).”
InfluentialMcMillan, H. J., Baranello, G., Farrar, M. A., Zaidman, C. M., Moreno, T., Waele, L. D., Jong, Y., Laugel, V., Quijano-Roy, S., Mercuri, E. M., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000210268 · Cited by 31
Peptide‐Oligonucleotide Nanohybrids Designed for Precise Gene Therapy of Rheumatoid Arthritis
Wang, Q., Peng, X., Gao, X., Qin, Y., Li, W., Wu, Z., Lao, Z., Gao, A., Mao, Z., Xu, Y., et al. (2025) · Advanced Materials · doi:10.1002/adma.202500883 · Cited by 39
Neuronal activity regulates DROSHA via autophagy in spinal muscular atrophy
Gonçalves, I. D. C. G., Brecht, J., Thelen, M. P., Rehorst, W. A., Peters, M., Lee, H. J., Motameny, S., Torres‐Benito, L., Ebrahimi‐Fakhari, D., Kononenko, N. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26347-y · Cited by 29
Pan, X., Sands, S. A., Yue, Y., Zhang, K., LeVine, S. M., & Duan, D. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.008 · Cited by 30
Villalón, E., Kline, R., Smith, C. E., Lorson, Z. C., Osman, E. Y., O’Day, S., Murray, L. M., & Lorson, C. L. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz188 · Cited by 32
Two-Plasmid Packaging System for Recombinant Adeno-Associated Virus
Tang, Q., Keeler, A. M., Zhang, S., Su, Q., Lyu, Z., Cheng, Y., Gao, G., & Flotte, T. R. (2020) · BioResearch open access · doi:10.1089/biores.2020.0031 · Cited by 33
CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model
Tokuoka, H., Imae, R., Nakashima, H., Manya, H., Masuda, C., Hoshino, S., Kobayashi, K., Lefeber, D. J., Matsumoto, R., Okada, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29473-4 · Cited by 30
Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich’s Ataxia
Sivakumar, A., & Cherqui, S. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.903139 · Cited by 40
“The promise of AAV9 serotype carrying human SMN1 in improving survival and motor functions of wheelchair-bound children with spinal muscular atrophy (SMA) (Mendell et al., 2017) spurred translation of several explorative research to clinical trials for neurodegenerative diseases with AAVs.”
BackgroundScarrott, J. M., Johari, Y. B., Pohle, T. H., Liu, P., Mayer, A., & James, D. C. (2022) · Biotechnology Journal · doi:10.1002/biot.202200450 · Cited by 31
“, 6 × 1013–2 × 1014 vector genomes/kg[3]) has limited the economic viability of AAV gene therapies despite evidence of promising clinical efficacy.”
BackgroundClinical Pharmacology Considerations on Recombinant Adeno‐Associated Virus–Based Gene Therapy
Sun, K., & Liao, M. Z. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2141 · Cited by 37
Yang, D.-L., Ruan, Y.-Y., & Chen, Y. (2023) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.16340 · Cited by 23
Therapeutic strategies for autism: targeting three levels of the central dogma of molecular biology
Hong, D., & Iakoucheva, L. M. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02356-y · Cited by 36
“In a phase 3 clinical trial, this AAV9 vector has found success in intravenously delivering the SMA1 transgene—effectively restoring motor functions in SMA patients [157, 158].”
BackgroundIdentifying Biomarkers of Spinal Muscular Atrophy for Further Development
Glascock, J., Darras, B. T., Crawford, T. O., Sumner, C. J., Kolb, S. J., DiDonato, C. J., Elsheikh, B., Howell, K., Farwell, W. R., Valente, M., et al. (2023) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-230054 · Cited by 31
Retson, L., Tiwari, N. R., Vaughn, J. A., Bernes, S. M., Adelson, P. D., Mansfield, K. G., Libertini, S., Kuzmiski, J. B., Alecu, I., Gabriel, R., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.08.013 · Cited by 29
“Mendell et al. 12 reported preliminary data from 15 patients with SMA type 1 treated with a single dose of onasemnogene abeparvovec in an open-label, phase 1 study (START trial; ClinicalTrials.gov: NCT02122952).”
Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III
Jauze, L., Monteillet, L., Mithieux, G., Rajas, F., & Ronzitti, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.102 · Cited by 34
Dai, W., Wu, J., Wang, D., & Wang, J. (2020) · Gene Therapy · doi:10.1038/s41434-020-0128-x · Cited by 31
Servais, L., Baranello, G., Scoto, M., Daron, A., & Oskoui, M. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1904889 · Cited by 33
“reported in the clinical trials with the intravenous delivery of onasemnogene abeparvovec were transient elevation in serum transaminases and potential hepatotoxicity, as well as a transient thrombocytopenia [26].”
Gene therapy in pediatrics – Clinical studies and approved drugs (as of 2023)
Gol, T. M., Zahedipour, F., Trosien, P., Ureña-Bailén, G., Kim, M., Antony, J. S., & Mezger, M. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122685 · Cited by 33
Engineering challenges and translational opportunities in emerging gene delivery platforms
Ma, Y., Dong, S., Wu, A., Jeong, S. D., Lee, A. S., Jiang, W., & Kim, B. Y. S. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01643-5 · Cited by 49
Metadata
- Authors
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K.
- Affiliations
- Abigail Wexner Research Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-02
- Volume
- 377
- Issue
- 18
- Pages
- 1713-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2765253110
- Cited by
- 2,381
- References
- 26
- Citations by year
- 2026: 205 · 2025: 232 · 2024: 292 · 2023: 270 · 2022: 289 · 2021: 347 · 2020: 298 · 2019: 246 · 2018: 172 · 2017: 16
- FWCI
- 115.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nationwide Children's Hospital
- AveXis
- Research Institute, Nationwide Children's Hospital
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy type 1, gene replacement therapy, adeno-associated virus vectors, SMN1, motor function, motor milestones, survival, CHOP INTEND, aminotransferase elevation, prednisolone, treatment efficacy and safety
- MeSH terms
- Dependovirus, Female, Genetic Vectors, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Liver Diseases, Male, Motor Skills, Respiration, Artificial, Spinal Muscular Atrophies of Childhood, Genetic Therapy, Cohort Studies, Nutritional Support, Disease-Free Survival, Survival of Motor Neuron 1 Protein, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.